After a bruising year, Aeterna Zentaris inks a $24M upfront US pact for growth hormone asset
Over the past year Aeterna Zentaris $AEZS has watched its lead drug go down in flames on a failed Phase III trial, gone back to hunt an approval for its old lead program — which had also failed — and got into a knock down and drag out fight with its ex-CEO over allegations he was trying to purloin their key remaining asset.
Today, the company is announcing that it’s handing off US and Canadian rights to Macrilen (macimorelin) — its sole asset outside of preclinical development — in exchange for a $24 million cash upfront and $179 million in milestones, including a $5 million bonus for a pediatric approval.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.